Study for the effect of visceral fat reduction by SGLT2 inhibitor Ipragliglozinin patients with type 2 diabetes

Trial Profile

Study for the effect of visceral fat reduction by SGLT2 inhibitor Ipragliglozinin patients with type 2 diabetes

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2016

At a glance

  • Drugs Ipragliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Apr 2015 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 03 Mar 2015 Status changed from not yet recruiting to active, no longer recruiting, according University Hospital Medical Information Network - Japan
    • 10 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top